US 11,939,374 B2
Treatment of fibrosis
Stuart Alexander Cook, Singapore (SG); and Sebastian Schaefer, Singapore (SG)
Assigned to Singapore Health Services PTE LTD., Singapore (SG); and National University of Singapore, Singapore (SG)
Filed by Singapore Health Services PTE LTD., Singapore (SG); and National University of Singapore, Singapore (SG)
Filed on Dec. 2, 2020, as Appl. No. 17/110,094.
Application 15/988,463 is a division of application No. 15/381,622, filed on Dec. 16, 2016, granted, now 10,035,852.
Application 17/110,094 is a continuation of application No. 16/055,270, filed on Aug. 6, 2018, granted, now 10,894,825.
Application 16/055,270 is a continuation of application No. 15/988,463, filed on May 24, 2018, granted, now 10,106,603.
Claims priority of application No. 1522186 (GB), filed on Dec. 16, 2015.
Prior Publication US 2021/0188962 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01)
CPC C07K 16/244 (2013.01) [C07K 14/5428 (2013.01); C07K 14/7155 (2013.01); C07K 16/2866 (2013.01); C12N 15/1136 (2013.01); C12N 15/1138 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/32 (2013.01); C07K 2319/43 (2013.01); C12N 2310/14 (2013.01)] 15 Claims
 
1. A method of treating fibrosis in a human subject, the method comprising administering to the human subject in need of treatment, a therapeutically effective amount of a human or humanized monoclonal anti-human Interleukin 11 (IL-11) antibody which inhibits IL-11 mediated signaling;
wherein an antibody that inhibits IL-11 mediated signaling is an antibody which inhibits transforming growth factor beta 1 (TGF(31)-mediated activation of human fibroblasts to alpha smooth muscle actin (αSMA)-positive fibroblasts.